A Phase I Study of HDM201 in Patients with Advanced Cancers and a Normal TP53 Gene

Protocol
14-139
Full Title
A Phase I, Open Label, Multicenter, Dose-escalation Study of Oral HDM201 in Adult Patients with Advanced Solid and Hematological Tumors Characterized by Wild-type TP53
Phase
I
Purpose

The p53 protein normally acts to control cell growth. Many tumor cells find ways to prevent p53 from working, however. HDM201 is an investigational drug that may restore normal function to the p53 protein, causing tumor cells to weaken or die. In order for the drug to work, patients must have a normal (“wild-type”) version of the gene that governs the production of p53, called TP53.

The purpose of this study is to find the highest dose of HDM201 that can be given safely in patients with advanced solid tumors and blood cancers and normal TP53. HDM201 is taken orally (by mouth).

Eligibility

To be eligible for this study, patients must meet several criteria, including but not limited to the following:

For more information about this study and to inquire about eligibility, please contact Dr. David Hyman at 646-888-4226.

Disease(s)
Germ Cell Tumors
Hematology: Hematologic Malignancies
Hematology: Myelodysplastic Syndrome
Kidney Cancer
Leukemia
Melanoma
Sarcomas: Osteosarcoma
Sarcomas: Soft Tissue Sarcoma
Solid Tumors
Locations